



TECH CENTER 1600/2900

ATTORNEY DOCKET NO. 07004/002002

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Jong Y. Lee Serial No.: 09/016,159

Art Unit: 1646

Examiner:

Filed Title

: January 30, 1998

: PURIFIED HUMAN ERYTHROPOIETIN RECEPTOR PROTEIN

FRAGMENT AND ANTIBODIES DERVIED THEREFROM

Assistant Commissioner for Patents

Washington, DC 20231

NOTIFICATION OF ERROR ON FILING RECEIPT

Dear Sir:

We received a Filing Receipt for the above-noted case. The Filing Receipt does not include the complete continuing data for this patent application. The correct continuing data should be:

> This application is a continuation of U.S. application serial no. 08/876,227, filed June 16, 1997, which is a continuation of U.S. application serial no. 08/734,097, filed October 21, 1996, which is a continuation of U.S. application serial no. 08/460,525, filed June 2, 1995, which is a divisional of U.S. application serial no. 08/106,815, filed August 16, 1993.

If there are any charges, or any credits, please apply them to Deposit Accout 06-1050.

Respectfully submitted,

Date: March 20, 1998

Mark S. Ellinger

Reg. No. 34,812

Fish & Richardson P.C., P.A. 60 South Sixth Street, Suite 3300 Minneapolis, MN 55402

Telephone: 612/335-5070 Facsimile: 612/288-9696

13738.M11

Date of Deposit I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.









United States Patent and Trademark Office

COMMISSIONER FOR PATENTS

United States Patent and Trademark Office

07004-00200

WASHINGTON, D.C. 20231 www.uspto.gov

APPLICATION NUMBER FILING DATE **GRP ART UNIT** FIL FEE REC'D ATTY.DOCKET.NO DRAWINGS TOT CLAIMS IND CLAIMS **Q7004** 09/016,159 01/30/1998 605 1647 6 7 4 002002

CONFIRMATION NO. 6621

CORRECTED FILING RECEIPT *OC000000006494537*

FISH & RICHARDSON P.C., P.A. **60 SOUTH SIXTH STREET** SLUTE 3300

EAPOLIS,, MN 55402

2001 PRACTICE SYSTEMS

Date Mailed: 08/29/2001

TRADER DE LE SE LE CONSIDER DE LA CONTROL DE LA CONSIDER DE LA CON you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If y u received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

JONG Y. LEE, MINNEAPOLIS, MN;

D mestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 08/876,227 06/16/1997 ABN

Foreign Applications

If Required, Foreign Filing License Granted 03/06/1998

CPA filed on: 04/26/2001

Projected Publication Date: 12/06/2001

N n-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

PURIFIED HUMAN ERYTHROPOIETIN RECEPTOR PROTEIN FRAGMENT AND ANTIBODIES DERIVED THEREFROM



435

Data entry by: NGUYEN, TRAC

Team : OIPE

Date: 08/29/2001



GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231

US 090161590MP1



Creation date: 01-05-2004

Indexing Officer: TDANG5 - TIEN DANG

Team: OIPEBackFileIndexing

Dossier: 09016159

Legal Date: 12-31-2001

No.	Doccode	Number of pages
1	LET.	4

Total number of pages: 4

Remarks:

Order of re-scan issued on